BG40142A3 - Method for preparing piperazine derivatives - Google Patents

Method for preparing piperazine derivatives

Info

Publication number
BG40142A3
BG40142A3 BG057771A BG5777182A BG40142A3 BG 40142 A3 BG40142 A3 BG 40142A3 BG 057771 A BG057771 A BG 057771A BG 5777182 A BG5777182 A BG 5777182A BG 40142 A3 BG40142 A3 BG 40142A3
Authority
BG
Bulgaria
Prior art keywords
piperazine derivatives
preparing piperazine
preparing
derivatives
formulated
Prior art date
Application number
BG057771A
Other languages
Bulgarian (bg)
English (en)
Inventor
Rudi Beyerle
Heinz Bender
Ursula Schindler
Rolf-Eberhard Nitz
Piero Martorana
Original Assignee
Cassella Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassella Ag filed Critical Cassella Ag
Publication of BG40142A3 publication Critical patent/BG40142A3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG057771A 1981-08-20 1982-08-18 Method for preparing piperazine derivatives BG40142A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813132882 DE3132882A1 (de) 1981-08-20 1981-08-20 Neue piperazinone, ihre herstellung und verwendung

Publications (1)

Publication Number Publication Date
BG40142A3 true BG40142A3 (en) 1986-10-15

Family

ID=6139695

Family Applications (1)

Application Number Title Priority Date Filing Date
BG057771A BG40142A3 (en) 1981-08-20 1982-08-18 Method for preparing piperazine derivatives

Country Status (23)

Country Link
US (1) US4598079A (da)
EP (1) EP0072932B1 (da)
JP (1) JPS5839673A (da)
KR (1) KR880001622B1 (da)
AT (1) ATE49596T1 (da)
AU (1) AU556064B2 (da)
BG (1) BG40142A3 (da)
CA (1) CA1190227A (da)
DD (1) DD206991A5 (da)
DE (2) DE3132882A1 (da)
DK (1) DK154765C (da)
ES (1) ES8305739A1 (da)
FI (1) FI76325C (da)
GR (1) GR78362B (da)
HU (1) HU190696B (da)
IL (1) IL66566A (da)
NO (1) NO822643L (da)
NZ (1) NZ200761A (da)
PH (1) PH18447A (da)
PL (1) PL139405B1 (da)
PT (1) PT75444B (da)
RO (1) RO85267B (da)
ZA (1) ZA826031B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772705A (en) * 1985-07-25 1988-09-20 Pennwalt Corporation Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines
JPS62198671A (ja) * 1986-02-25 1987-09-02 Toyo Jozo Co Ltd 1−置換アルキル1,2−ジヒドロ−2−ピラジノン誘導体
DE3817198A1 (de) * 1988-05-20 1989-11-30 Cassella Ag Thienyl-piperazinone, ihre herstellung und verwendung
US5238938A (en) * 1989-02-10 1993-08-24 Otsuka Pharmaceutical Co., Ltd. Indole derivatives
WO1990009380A1 (fr) * 1989-02-10 1990-08-23 Otsuka Pharmaceutical Co., Ltd. Derives d'indole, leur preparation et medicament les contenant destine a la prevention et au traitement de la nephrite
DE3908547A1 (de) * 1989-03-16 1990-09-20 Cassella Ag Thienylessigsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie diese enthaltende arzneimittel und deren herstellung
DE3909379A1 (de) * 1989-03-22 1990-09-27 Cassella Ag Thienylpiperazine, verfahren zu ihrer herstellung, ihre verwendung sowie diese enthaltende arzneimittel und deren herstellung
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
DE4408530A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Verfahren zur Herstellung von Aminoethylglycin
CA2198084C (en) 1994-08-25 2000-03-28 Timothy P. Burkholder Novel substituted piperidines useful for the treatment of allergic diseases
FI973671A0 (fi) * 1995-03-15 1997-09-12 Hoechst Marion Roussel Inc Heterosyklisen substituentin sisältäviä piperatsinonijohdoksia takykiniinireseptoriantagonisteina
JP3950170B2 (ja) * 1995-04-13 2007-07-25 アベンティス・ファーマスーティカルズ・インコーポレイテッド タキキニン受容体アンタゴニスト活性を有する新規な置換されたピペラジン誘導体
GB9510600D0 (en) * 1995-05-25 1995-07-19 Fujisawa Pharmaceutical Co Piperazine derivatives
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
WO1997036591A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
IN190478B (da) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
WO2003024401A2 (en) * 2001-09-18 2003-03-27 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197089B (de) * 1962-01-25 1965-07-22 Richardson Merrell Inc Verfahren zur Herstellung von 2-Oxo-1, 2, 5, 6-tetrahydropyrazinen
US3390139A (en) * 1964-03-04 1966-03-11 Rohm & Haas Nu-vinyl-2-piperazinones
US3935214A (en) * 1968-07-26 1976-01-27 Donau-Pharmazie Gesellschaft M.B.H. 2-or 3 keto-3-or-2-phenyl-1,4-disubstituted piperazines
DE2438619A1 (de) * 1974-08-12 1976-02-26 Knoll Ag Verfahren zur herstellung von substituierten 2-ketopiperazin-derivaten
AT356122B (de) * 1978-10-17 1980-04-10 Yoshitomi Pharmaceutical Verfahren zur herstellung von neuen pyridazinonderivaten und ihren salzen mit saeuren

Also Published As

Publication number Publication date
FI76325C (fi) 1988-10-10
AU8742282A (en) 1983-02-24
RO85267B (ro) 1984-10-30
DD206991A5 (de) 1984-02-15
JPS5839673A (ja) 1983-03-08
KR840001158A (ko) 1984-03-28
ES515120A0 (es) 1983-05-01
DE3280088D1 (de) 1990-02-22
DK342382A (da) 1983-02-21
PT75444B (de) 1985-01-04
HU190696B (en) 1986-10-28
ES8305739A1 (es) 1983-05-01
EP0072932B1 (de) 1990-01-17
FI822698A0 (fi) 1982-08-02
PL139405B1 (en) 1987-01-31
EP0072932A3 (en) 1984-03-21
DK154765C (da) 1989-05-16
DK154765B (da) 1988-12-19
NZ200761A (en) 1985-04-30
PT75444A (de) 1982-09-01
AU556064B2 (en) 1986-10-23
US4598079A (en) 1986-07-01
FI822698L (fi) 1983-02-21
NO822643L (no) 1983-02-21
RO85267A (ro) 1984-09-29
PL237952A1 (en) 1983-03-14
FI76325B (fi) 1988-06-30
IL66566A0 (en) 1982-12-31
ATE49596T1 (de) 1990-02-15
EP0072932A2 (de) 1983-03-02
GR78362B (da) 1984-09-26
ZA826031B (en) 1983-07-27
PH18447A (en) 1985-07-08
IL66566A (en) 1985-12-31
KR880001622B1 (ko) 1988-09-02
DE3132882A1 (de) 1983-03-03
CA1190227A (en) 1985-07-09

Similar Documents

Publication Publication Date Title
BG40142A3 (en) Method for preparing piperazine derivatives
BG40652A3 (en) Method for preparing (1- arylcyclobutyl) alkylamines
BG40655A3 (en) Method for preparing n- (bi heterocyclic)- 4- piperidineamines
BG41130A3 (en) Method for preparing 8- chlor-1, 5- benzo- thiazepine derivatives
BG38787A3 (bg) Метод за получаване на карбоксиалкилни дипептиди
BG37075A3 (bg) Метод за получаване на производни на пролина
BG40654A3 (bg) Метод за получаване на циклоалкилтриазоли
BG40815A3 (bg) Метод за получаване на пептиди
BG42185A3 (en) Method for preparing pyridylic compounds
BG35330A3 (bg) Метод за получаване на 3-йодметилцефалоспорини
BG39976A3 (en) Method for preparing benzamides
BG42355A3 (en) Method for preparing aminoguanidinic derivatives
BG36932A3 (bg) Метод за получаване на 1-(3-хидрокси-4-метаксибензоил)-3- хидрокси-2-пиролидинон
BG40807A3 (en) Method for preparing n- phenylcarbamates
BG40147A3 (bg) Метод за получаване на хетероциклични съединения
BG40803A3 (bg) Метод за получаване на арилциклобутилалкиламинови производни
BG39639A3 (bg) Метод за получаване на 1н, 3н- пироло/1,2-с/ тиазолови производни
BG35464A3 (en) Method preparing fluorene derivatives
BG40315A3 (bg) Метод за получаване на ауронови производни
BG33292A3 (bg) Метод за получаване на пенамсулфоокисни производни
BG38637A3 (en) Method for preparing 2- exo- hydroxy- 7- oxabicyclo [2, 2, 1] heptanes
BG36935A3 (en) Method for preparing benzodiazepine compounds
BG38940A3 (en) Method for preparing penicillanoyloxymethyl penicillanate- 1, 1- dioxide
BG40808A3 (bg) Метод за получаване на производни на пиролидина
BG40143A3 (en) Method for preparing acetamide derivatives